DOP2001000308A - Inhibidores de fosfodiesterasa-4 de 8-arilquinolina sustituida - Google Patents

Inhibidores de fosfodiesterasa-4 de 8-arilquinolina sustituida

Info

Publication number
DOP2001000308A
DOP2001000308A DO2001000308A DO2001000308A DOP2001000308A DO P2001000308 A DOP2001000308 A DO P2001000308A DO 2001000308 A DO2001000308 A DO 2001000308A DO 2001000308 A DO2001000308 A DO 2001000308A DO P2001000308 A DOP2001000308 A DO P2001000308A
Authority
DO
Dominican Republic
Prior art keywords
acid
arilquinoline
replaced
phosphodiesterase inhibitors
substituted
Prior art date
Application number
DO2001000308A
Other languages
English (en)
Inventor
Dwight Macdonald
Anant Vailaya
David A Conlon
Guo Jie Ho
Helene Perrier
Roch Thibert
Elizabeth Kwong
Sophie-Dorothee Clas
Original Assignee
Merck & Co Inc
Merck Frosst Canada Y Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Merck Frosst Canada Y Co filed Critical Merck & Co Inc
Publication of DOP2001000308A publication Critical patent/DOP2001000308A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Las sales novedosas de acido sulfúrico, acido metansulfonico, acido p-toluensulfonico, acido 2-naftalensulfonico, acido clorhídrico o acido bencensulfonico de 8-arilquinolinas sustituidas, donde el grupo arilo en la posición 8 contiene un grupo sustitúyente alquenilo sustituido son inhibidoras de PDE4.
DO2001000308A 2000-12-20 2001-12-18 Inhibidores de fosfodiesterasa-4 de 8-arilquinolina sustituida DOP2001000308A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25680300P 2000-12-20 2000-12-20

Publications (1)

Publication Number Publication Date
DOP2001000308A true DOP2001000308A (es) 2002-07-15

Family

ID=22973639

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2001000308A DOP2001000308A (es) 2000-12-20 2001-12-18 Inhibidores de fosfodiesterasa-4 de 8-arilquinolina sustituida

Country Status (28)

Country Link
US (1) US6740666B2 (es)
EP (1) EP1363635B1 (es)
JP (1) JP2004521921A (es)
KR (1) KR20030063456A (es)
CN (1) CN100508978C (es)
AR (1) AR035514A1 (es)
AT (1) ATE428420T1 (es)
AU (1) AU2001297603B2 (es)
BG (1) BG107900A (es)
BR (1) BR0116372A (es)
CA (1) CA2431549A1 (es)
CZ (1) CZ20031738A3 (es)
DE (1) DE60138421D1 (es)
DO (1) DOP2001000308A (es)
EA (1) EA006607B1 (es)
EE (1) EE200300266A (es)
HU (1) HUP0400654A3 (es)
IL (1) IL156479A0 (es)
JO (1) JO2317B1 (es)
MX (1) MXPA03005673A (es)
MY (1) MY136792A (es)
NO (1) NO20032807L (es)
NZ (1) NZ526376A (es)
PE (1) PE20020787A1 (es)
PL (1) PL362564A1 (es)
SK (1) SK7732003A3 (es)
WO (1) WO2002069970A1 (es)
ZA (1) ZA200304672B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4141838B2 (ja) * 2000-12-20 2008-08-27 メルク エンド カムパニー インコーポレーテッド 置換８−アリールキノリニウムベンゼンスルホネートを生成するための方法
AU2003209896A1 (en) * 2002-03-18 2003-09-29 Merck Frosst Canada And Co. Hetero-bridge substituted 8-arylquinoline pde4 inhibitors
CA2515407A1 (en) * 2003-02-10 2004-08-26 Todd Ovokaitys Enhanced bioavailability of nutrients, pharmaceutical agents, and other bioactive substances through laser resonant homogenization or modification of molecular shape or crystalline form
GB0307863D0 (en) * 2003-04-04 2003-05-14 Merck Sharp & Dohme Therapeutic treatment
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
CN100425591C (zh) * 2005-09-26 2008-10-15 山东大学 含有磺酰基二苯基乙烯桥化合物及其制法和药物应用
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
SI2363130T1 (sl) 2006-07-05 2014-09-30 Takeda Gmbh Kombinacija inhibitorjev HMG-CoA reduktaze atorvastatina ali simvastatina z inhibitorjem fosfodiesteraze 4, kot je roflumilast, za zdravljenje vnetnih pljučnih bolezni
US8258154B2 (en) * 2006-07-07 2012-09-04 Kalypsys Inc. Bicyclic heteroaryl inhibitors of PDE4
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
MX2009010946A (es) * 2007-04-11 2009-10-29 Alcon Res Ltd Uso de un inhibidor del factor de necrosis tumoral alfa mas una antihistamina para tratar rinitis alergica y conjuntivitis alergica.
EP2674417A3 (en) * 2007-11-21 2014-04-09 Decode Genetics EHF Biaryl PDE4 inhibitors for treating inflammation
EP2482798A1 (en) * 2009-10-01 2012-08-08 Alcon Research, Ltd. Olopatadine compositions and uses thereof
US8367829B2 (en) 2010-05-10 2013-02-05 Gilead Sciences, Inc. Bi-functional pyrazolopyridine compounds
EP2569285A1 (en) 2010-05-10 2013-03-20 Gilead Sciences, Inc. Bifunctional quinoline derivatives
SG11202106517WA (en) 2018-12-28 2021-07-29 Regeneron Pharma Treatment of respiratory disorders with arachidonate15-lipoxygenase (alox15) inhibitors
US20240199661A1 (en) * 2021-03-31 2024-06-20 Riboscience Llc Bicyclic heteroaryl phosphonate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9212673D0 (en) 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9212693D0 (en) 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
DE59304166D1 (de) 1992-07-01 1996-11-21 Hoechst Ag 3,4,5-Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9222253D0 (en) 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9226830D0 (en) 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
US5622977A (en) 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
DE4306152A1 (de) 1993-02-27 1994-09-01 Hoechst Ag Positiv arbeitendes strahlungsempfindliches Gemisch und damit hergestelltes Aufzeichnungsmaterial
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US5455252A (en) 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
DE4318756A1 (de) 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9326600D0 (en) 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
GB9326173D0 (en) 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
DE69433594T2 (de) 1993-12-22 2004-08-05 Celltech R&D Ltd., Slough Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
EP0765867A1 (de) 1995-09-27 1997-04-02 Hoechst Aktiengesellschaft Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhytmika oder Diagnostikum sowie sie enthaltendes Medikament
GB9526246D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
DE19622370A1 (de) 1996-06-04 1997-12-11 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9625184D0 (en) 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
JP4099237B2 (ja) 1996-12-11 2008-06-11 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト カルパインインヒビターとしてのケトベンズアミド
JPH11209350A (ja) 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
MY134008A (en) * 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
JP4415360B2 (ja) 2000-01-28 2010-02-17 エプソントヨコム株式会社 縦結合弾性表面波フィルタ

Also Published As

Publication number Publication date
HUP0400654A2 (hu) 2004-06-28
IL156479A0 (en) 2004-01-04
US6740666B2 (en) 2004-05-25
EE200300266A (et) 2003-10-15
NO20032807D0 (no) 2003-06-19
CN100508978C (zh) 2009-07-08
PL362564A1 (en) 2004-11-02
NZ526376A (en) 2005-02-25
BG107900A (bg) 2004-06-30
EP1363635B1 (en) 2009-04-15
HUP0400654A3 (en) 2011-07-28
AU2001297603B2 (en) 2006-02-16
NO20032807L (no) 2003-08-15
MXPA03005673A (es) 2003-10-06
PE20020787A1 (es) 2002-09-10
ZA200304672B (en) 2004-04-21
JP2004521921A (ja) 2004-07-22
ATE428420T1 (de) 2009-05-15
CA2431549A1 (en) 2002-09-12
SK7732003A3 (en) 2003-11-04
US20020143032A1 (en) 2002-10-03
KR20030063456A (ko) 2003-07-28
WO2002069970A1 (en) 2002-09-12
EP1363635A1 (en) 2003-11-26
AR035514A1 (es) 2004-06-02
CZ20031738A3 (cs) 2003-11-12
JO2317B1 (en) 2005-09-12
EA006607B1 (ru) 2006-02-24
EA200300706A1 (ru) 2003-12-25
DE60138421D1 (en) 2009-05-28
BR0116372A (pt) 2003-12-09
MY136792A (en) 2008-11-28
CN1551769A (zh) 2004-12-01

Similar Documents

Publication Publication Date Title
DOP2001000308A (es) Inhibidores de fosfodiesterasa-4 de 8-arilquinolina sustituida
DE69803907D1 (de) Fungizide 2-Methoxybenzophenone
NO2012021I2 (no) Perampanel eller salter eller hydrater derav
GT199900055A (es) Nuevas dihidropirimidinas2 heterocìclicamente sustituidas.
ES2184070T3 (es) Derivados de oximas sustituidas utiles como antagonistas de la neuroquinina.
SE0100902D0 (sv) Compounds
PT94568A (pt) Quinazolinonas substituidas como antagonistas da angiotensina ii
CR6079A (es) Trifluorometilpirrolcarboxamidas
BR0210030A (pt) Derivado de fenilpiridinacarbonilpiperazina
NO920767D0 (no) Pyranylcyanoguanidin-derivater
DE60027015D1 (en) Pseudoerythromycin-derivate
DZ2769A1 (fr) Composés tricycliques substitués.
UY27338A1 (es) Nuevos derivados de ácido sulfónico
DE69920923D1 (de) Anthranilsäurederivate
ATE403431T1 (de) Benzimidazolon-verbindungen
DE69813605D1 (de) Benzofuranderivate
DE60025744D1 (de) Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
ATE309220T1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2- carbonsäurederivate
DK0841326T3 (da) Fremgangsmåde til fremstilling af pyrimidinderivater
ATE277017T1 (de) 1,2-disubstituierte 1,4-dihydro-4-oxochinolin- verbindungen
BRPI0013751B8 (pt) processo para produção de derivados de ácido naftiridina-3-carboxílico.
DE60039695D1 (de) Antifucoidan antikörper
PT1133495E (pt) Semi-hidrocloreto do acido 8-ciano-1-ciclopropil-7-(1s,6s-2,8-diazabiciclo-¬4.3.0|-nonano-8-il)-6-fluoro-1,4-diidro-4-oxo-3-quinolinocarboxilico
BR0013094A (pt) Processo para a preparação de compostos 1,3-dicarbonìlicos acilados
PT1133496E (pt) Modificacao cristalina a de acido 8-ciano-1-ciclopropil-7-(1s,6s-2,8-diazabiciclo-¬4.3.0|nonan-8-il)-6-fluoro-1,4-di-hidro-4-oxo-3-quinolinocarboxilico